Morgan Stanley (MS)
Is MS Stock Worth Buying Post Q4 Earnings & Under Trump 2.0?
Morgan Stanley appears to be a promising bet after the release of Q4 results and under the new Trump-led administration. Read on to explore its potential.
Are You Looking for a Top Momentum Pick? Why Morgan Stanley (MS) is a Great Choice
Does Morgan Stanley (MS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Investors Heavily Search Morgan Stanley (MS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Morgan Stanley (MS). This makes it worthwhile to examine what the stock has in store.
Why Morgan Stanley (MS) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Morgan Stanley (MS) have what it takes?
Is Morgan Stanley (MS) Stock a Solid Choice Right Now?
Morgan Stanley (MS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Morgan Stanley (MS) Q4 2024 Earnings Call Transcript
Morgan Stanley (NYSE:MS ) Q4 2024 Earnings Conference Call January 16, 2025 8:30 AM ET Company Participants Ted Pick - CEO Sharon Yeshaya - CFO Conference Call Participants Glenn Schorr - Evercore Ebrahim Poonawala - Bank of America Brennan Hawken - UBS Mike Mayo - Wells Fargo Steven Chubak - Wolfe Research Christian Bolu - Autonomous Devin Ryan - Citizens JMP Dan Fannon - Jefferies Gerard Cassidy - RBC Operator Good morning. Welcome to Morgan Stanley's Fourth Quarter and Full Year 2024 Earnings Call.
Morgan Stanley (MS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Morgan Stanley (MS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Morgan Stanley (MS) Q4 Earnings and Revenues Beat Estimates
Morgan Stanley (MS) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $1.65 per share. This compares to earnings of $1.13 per share a year ago.
Exploring Analyst Estimates for Morgan Stanley (MS) Q4 Earnings, Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Morgan Stanley (MS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Surge in IB Activities & Solid Trading to Support MS' Q4 Earnings
Impressive IB performance, robust trading and lower rates will likely support Morgan Stanley's Q4 earnings.
Morgan Stanley (MS) Earnings Expected to Grow: Should You Buy?
Morgan Stanley (MS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan Stanley's top pick for 2025. He highlights the robust growth potential of Eli Lilly's drug Zepbound, which could become a $100 billion market opportunity.
